Compare SLDP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | AVIR |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.5M | 429.1M |
| IPO Year | 2021 | 2020 |
| Metric | SLDP | AVIR |
|---|---|---|
| Price | $2.47 | $5.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 2.2M | 216.2K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 5.56 | 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | $21,747,000.00 | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $48.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.98 | N/A |
| 52 Week Low | $1.98 | $2.78 |
| 52 Week High | $8.86 | $6.45 |
| Indicator | SLDP | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 48.40 |
| Support Level | $2.22 | $5.13 |
| Resistance Level | $2.50 | $5.79 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 53.57 | 25.56 |
Solid Power Inc develops solid-state battery technology and manufacturing processes. Its sulfide-based solid electrolyte material replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells and enables improvement in energy density, battery life and safety performance. The company produces electrolytes on two pilot manufacturing lines using a batch manufacturing process for customer sampling and internal cell development, and manufactures solid-state cells on pre-pilot and pilot cell manufacturing lines. Its cell manufacturing processes are developed around industry-standard lithium-ion battery manufacturing processes and equipment, and it manufactures all cell designs, including cathodes and anodes, using materials sourced from external suppliers.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.